|
Ulrich Sigwart (born March 9, 1941 in Germany) is a cardiologist known for his pioneering role in the conception and clinical use of vascular stents. He also introduced a non-surgical intervention for the treatment of hypertrophic obstructive cardiomyopathy. == Biography == Sigwart's family has its origins in Tübingen (Germany) where several members played an important role at the local university. Most of his ancestors were doctors, philosophers, or theologians, and a street in Tübingen is named after one of them.〔http://onlinelibrary.wiley.com/doi/10.1002/clc.20322/pdf〕 He had his medical education in Freiburg (Germany), Basel (Switzerland) and Munster (Germany). After some years in the U.S. (Boston and Houston) followed by additional training in Zurich (Switzerland) he was charged in 1973 to set up an invasive cardiology program at the Gollwitzer-Meier Institute in Bad Oeynhausen in Germany, which became the nidus for the Heart and Diabetes Center North-Rhine Westphalia. From 1979 to 1989 he headed the section of invasive cardiology at the University Hospital in Lausanne (Switzerland). From 1989 to 2001 he was director of the department of invasive cardiology at the Royal Brompton Hospital in London and occupied the chair of cardiology at the University of Geneva (Switzerland) until his retirement in 2006. Sigwart believed in the concept of intravascular scaffolding. In 1987, after several years of preliminary work in animals, he published a landmark paper on the use intravascular stents in humans to prevent occlusion and re-stenosis after angioplasty of coronary and peripheral arteries.〔Sigwart U, Puel J, Mirkovitch V, Joffre F, Kappenberger L: Intravascular stents to prevent occlusion and restenosis after transluminal angioplasty. N Engl J Med 1987;316:701–706〕 In 1994 he introduced percutaneous alcohol septal ablation (ASA, TASH, PTSMA), a non-surgical method for the treatment of hypertrophic obstructive cardiomyopathy, which often allows symptomatic patients to avoid open heart surgery.〔Sigwart U: Non-surgical myocardial reduction for hypertrophic obstructive myocardial infarction. Lancet 1995;346:211–214〕 During the years 1974–1978 he created the basis for the automated analysis of hemodynamic data and studied the repercussions of myocardial ischemia 〔Sigwart U, Grbic M, Payot M, Goy J-J, Essinger A, et al.: Ischemic events during coronary artery balloon occlusion. In: Rutishauser W, Roskamm H, eds. Silent Myocardial Ischemia. Berlin: SpringerVerlag; 1984; 29–36〕 and the performance of artificial heart valves. 抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』 ■ウィキペディアで「Ulrich Sigwart」の詳細全文を読む スポンサード リンク
|